Docsity
Docsity
Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity

Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan

Guidelines and tips
Guidelines and tips
Sell on Docsity
Sell on Docsity
Docsity AI
Docsity AI
Log inSign up

Prepare for your exams

Study with the several resources on Docsity

Find documents

Prepare for your exams with the study notes shared by other students like you on Docsity

Search for your university

Find the specific documents for your university's exams

Docsity AINEW

Summarize your documents, ask them questions, convert them into quizzes and concept maps

Explore questions

Clear up your doubts by reading the answers to questions asked by your fellow students

Earn points to download

Earn points by helping other students or get them with a premium plan

Share documents
download point icon20 Points

For each uploaded document

Answer questions
download point icon5 Points

For each given answer (max 1 per day)

All the ways to get free points
Get points immediately

Choose a premium plan with all the points you need

Study Opportunities

Choose your next study program

Get in touch with the best universities in the world. Search through thousands of universities and official partners

Community

Ask the community

Ask the community for help and clear up your study doubts

Free resources

Our save-the-student-ebooks!

Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors

PCOA EXAM PRACTICE PRACTICE SCRIPT UPDATED 2026 TESTED SOLUTIONS, Exams of Medical Microbiology

Liberty University (LU)Medical Microbiology

PCOA EXAM PRACTICE PRACTICE SCRIPT UPDATED 2026 TESTED SOLUTIONS

Typology: Exams

2025/2026

Available from 02/05/2026

pass-withpolly7
pass-withpolly7 🇺🇸

27K documents

1 / 9

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
PCOA EXAM PRACTICE PRACTICE SCRIPT
UPDATED 2026 TESTED SOLUTIONS
⫸ Drug A is a full agonist for a specific receptor system; drug B is a
competitive antagonist for the same receptor system. If increasing doses
of drug B are co-administered with drug A, drug B will
A. increase the apparent Emax of drug A.
B. reduce the apparent Emax of drug A.
C. increase the apparent EC50 of drug A.
D. reduce the apparent EC50 of drug A Answer: C. Antagonists increase
the apparent EC50 of a drug by shifting the effect vs. concentration
curve to the right.
EC50 refers to the potency of a drug. The potency is the ability to cause
a functional change at a certain concentration. It is related to the affinity
of the drug for its receptor. A more potent drug needs a lower
concentration to cause the same functional change in a target structure.
⫸ Which of the following statements is correct for a receptor system
that exhibits a receptor reserve of 90%?
A. Partial agonists are not able to achieve maximum cellular response.
B. Only 10% of the available receptors need to be occupied by a full
agonist to achieve maximum cellular response.
C. More than 99% of the receptors need to be occupied by a competitive
antagonist to have an effect on the dose-response relationship of a full
agonist.
pf3
pf4
pf5
pf8
pf9

Partial preview of the text

Download PCOA EXAM PRACTICE PRACTICE SCRIPT UPDATED 2026 TESTED SOLUTIONS and more Exams Medical Microbiology in PDF only on Docsity!

PCOA EXAM PRACTICE PRACTICE SCRIPT

UPDATED 2026 TESTED SOLUTIONS

⫸ Drug A is a full agonist for a specific receptor system; drug B is a competitive antagonist for the same receptor system. If increasing doses of drug B are co-administered with drug A, drug B will A. increase the apparent Emax of drug A. B. reduce the apparent Emax of drug A. C. increase the apparent EC50 of drug A. D. reduce the apparent EC50 of drug A Answer: C. Antagonists increase the apparent EC50 of a drug by shifting the effect vs. concentration curve to the right. EC50 refers to the potency of a drug. The potency is the ability to cause a functional change at a certain concentration. It is related to the affinity of the drug for its receptor. A more potent drug needs a lower concentration to cause the same functional change in a target structure. ⫸ Which of the following statements is correct for a receptor system that exhibits a receptor reserve of 90%? A. Partial agonists are not able to achieve maximum cellular response. B. Only 10% of the available receptors need to be occupied by a full agonist to achieve maximum cellular response. C. More than 99% of the receptors need to be occupied by a competitive antagonist to have an effect on the dose-response relationship of a full agonist.

D. Only 90% in the receptor reserve is available for interaction with competitive antagonists. Answer: B. Only 10% of the available receptors need to occupied by a full agonist to achieve maximum cellular response. In a system with spare receptors or receptor reserve, only a fraction of available receptors needs to be stimulated to achieve the maximum pharmacologic response. ⫸ EC50 is a measure of A. the intrinsic activity of a drug. B. the efficacy of a drug. C. the potency of a drug. D. the dissociation rate of a drug-receptor complex. Answer: C. The concentration at half maximum effect, EC50, is a measure of drug potency, The more potent a drug is, the smaller the EC50. ⫸ Which of the following can act as an antagonist for a full agonist? A. Inverse agonist B. Partial agonist C. Less potent agonist D. Noncompetitive agonist Answer: B. Partial agonist A partial agonist can act as an antagonist for a full agonist because it occupies the receptors but has a reduced intrinsic activity.

Functional tolerance is characterized by a decreasing response to a repeated stimulus. ⫸ Which of the following statements is the therapeutically most important distinction between small molecule drugs and biologies such as therapeutic proteins? A. Therapeutic proteins are always substantially more expensive than small molecule drugs. B. Therapeutic proteins are not defined by structure and purity as are small molecule drugs, but by their production process, which may result in batch-to-batch variability. C. Therapeutic proteins are in contrast to small molecule drugs only available as intravenously administered dosage forms. D. Therapeutic proteins are always acting as antagonists. Answer: B. Therapeutic proteins are not defined by structure and purity as are small molecule drugs, but by their production process, which may result in batch-to- batch variability. Therapeutic proteins are produced in genetically modified living organisms and are defined by their production process. ⫸ An ACE inhibitor has a short elimination halflife of 3 hours and a wide therapeutic range. Why can it be administered once daily and still achieve therapeutic efficacy despite its short elimination half-life? A. The therapeutic efficacy of ACE inhibitors is independent of the administered dose and resulting drug concentration. B. After five elimination half-lives (15 hours), more than 90% of the administered drug has been eliminated, and the drug will not be effective

any more. Hence, the FDA made a mistake in approving this dosing regimen. C. Elimination half-life is irrelevant for designing dosing regimens. D. Because of the wide therapeutic range, the daily dose can be so high that even at the end of the 24-hour dosing interval, drug concentrations are still above the EC50 to maintain therapeutic efficacy Answer: D. Initial concentrations multiple times higher than the EC50 ensure therapeutically efficacious concentrations throughout the dosing interval despite the short half-life. ⫸ Which of the following statements regarding the concept of the therapeutic range is correct? A. Drug plasma concentrations below the lower limit of the therapeutic range are ineffective in all treated patients. B. If drug plasma concentrations are maintained within the therapeutic range, the drug's desired therapeutic effect is achieved in all treated patients. C. The therapeutic range defines a range of drug plasma concentration with high probability of desired clinical efficacy and low probability of unacceptable toxicity. D. If drug plasma concentrations always remain below the upper limit of the therapeutic range, none of the treated patients will experience drug- related toxicity Answer: C. The therapeutic range is a concentration range with high probability for efficacy and low probability for toxicity. ⫸ Assume a class of drug substances with the same pharmacokinetic characteristics and the same mechanism of action but different EC

A. in healthy subjects. B. in patients with the targeted disease. C. in special populations such as elderly patients or pediatric patients. D. in patients who have been cured from the targeted disease. Answer: A. Phase 1 studies establish the safety and tolerability of a new drug in healthy subjects. ⫸ The primary objective of phase III studies is to A. assess the pharmacokinetics of the drug in healthy individuals. B. determine the physicochemical stability of the dosage form. C. determine the pharmacoeconomic benefit of a new drug therapy. D. determine the efficacy and safety of a new drug therapy. Answer: D. Phase 3 study programs are aimed at determining the efficacy and safety of a new drug therapy. ⫸ Pharmacovigilance is an approach A. to increasing drug safety in the postmarketing phase. B. to preventing theft in the pharmacy. C. to increasing drug efficacy by switching nonresponders to different therapies. D. to preventing the use of drugs after their expiration date. Answer: A. Pharmacovigilance is a systematic approach to collecting, monitoring, researching, assessing, and evaluating ADR-related information from health care providers and patients.

⫸ Why is selectivity of a drug an important concept to minimize adverse drug reactions? A. Selectivity determines the fraction of patients who are nonresponders. B. Selectivity determines in which organ a drug accumulates. C. Selectivity determines the extent of a drug's interaction with off- target receptors. D. Selectivity determines how fast a drug is metabolized by hepatic enzymes. Answer: C. Selectivity is directly related to the frequency and severity of adverse drug reactions. ⫸ Two concurrently administered drugs are metabolized by the same hepatic enzyme system, CYP2D6. What conclusions should the pharmacist draw? A. There will certainly be a drug-drug interaction because both drugs use the same enzyme system. B. There is the potential for a drug-drug interaction, but it may not necessarily occur, depending on the doses of the drugs used and their affinities to CYP2D6. C. There will certainly be no drug-drug interactions because CYP2D6 is polymorphically expressed. D. There is the potential for a drug-drug interaction, but it will not occur if one drug is given by oral administration and the other drug is given by intravenous administration. Answer: B. The fact that two drugs are metabolized by the same enzyme system indicated only that the potential exists for drug-drug interaction. ⫸ The acceptance of a specific benefit-to-risk ratio (mark all that apply)